Where Can You Get Allergy Shots? Access Barriers, Rural Gaps & Alternatives

Allergy shots require a board-certified allergist or trained ENT to prescribe and supervise treatment, and these specialists are heavily concentrated in metropolitan areas. Research by Keet et al. in JACI In Practice (2017) confirmed that immunotherapy utilization is significantly lower in rural populations even when controlling for allergy prevalence — meaning access, not allergy burden, explains the gap. With approximately 4,000 board-certified allergists in the United States and much of the population outside driving range of one, rural patients face a two-part problem: finding a qualified provider and sustaining the weekly visit schedule during the build-up phase. Each build-up visit involves travel, wait time, a 30-minute observation period, and return travel — representing 2-4 hours or more per visit when distances are significant.

Yes — there are now several ways. Some allergists operate satellite injection clinics in underserved areas or partner with local primary care practices to administer injections under remote supervision, where the allergist prescribes the extract and protocol and a local nurse gives the injections. Many practices also conduct allergy testing via telehealth consultation (which expanded significantly post-COVID) before treatment. And for eligible maintenance patients, at-home SCIT through Curex delivers the same allergy-shot immunotherapy without office visits: a board-certified allergist confirms candidacy, the first injection and every dose change are supervised live over Zoom, and a prescribed epinephrine auto-injector is confirmed on hand before the first dose. Sublingual immunotherapy (SLIT drops under the tongue) remains a separate evidence-based modality for those who prefer a needle-free route.

Without insurance, allergy shots typically cost $1,000 to $4,000 per year. The major cost components are initial allergy testing ($150-$400), custom allergen extract preparation ($200-$600 per vial set, typically needed once or twice per year), and injection administration fees ($20-$60 per visit). During the build-up phase with weekly visits, the annual administration cost alone can reach $800-$2,400. Year one at the build-up frequency is the most expensive year; maintenance costs in years 2-5 are lower due to monthly (rather than weekly) visit frequency. Some allergists offer reduced rates for uninsured patients or payment plans — calling several practices for self-pay quotes is worthwhile. The total 5-year cost of SCIT is typically $5,000-$15,000 out of pocket without insurance.

The allergy testing consultation and initial evaluation can now often be conducted via telehealth — many allergists expanded telemedicine services during and after COVID. A telehealth visit can review your allergy history, interpret blood IgE results (ordered locally or through at-home testing), and determine whether immunotherapy is appropriate. Traditionally the injections themselves still had to be given in a medical setting; today, for eligible maintenance patients, at-home SCIT through Curex makes the shots themselves a telehealth-supported home treatment — the first injection and every dose change are supervised live over Zoom by the prescribing allergist, a prescribed epinephrine auto-injector is confirmed on hand before the first dose, and the serum is sterile-compounded to USP <797> standards. The build-up dose changes are Zoom-supervised, and the care team is reachable throughout.

Yes — research confirms that immunotherapy access disparities track along racial and socioeconomic lines. Keet et al. (2017) documented that immunotherapy utilization is significantly lower in rural populations and among patients with lower socioeconomic status, even after controlling for allergy prevalence and symptom severity. This mirrors broader healthcare access inequities. Factors contributing to these disparities include geographic distribution of allergists (concentrated in high-income urban areas), insurance status and coverage variability, ability to take time off work for weekly appointments (which disproportionately affects hourly workers), and transportation access. These structural barriers mean that effective treatments with a proven 85%+ success rate are not equally available to all patients who could benefit from them.

Yes, in more than one way. Some allergists prescribe allergen extracts and a written immunotherapy protocol that a separate local clinic — a closer satellite facility or a primary care practice with trained nurses — can use to administer injections, when that site has the required emergency equipment, trained personnel, and a physician available during injection hours. The prescribing allergist remains the responsible physician and must be contacted for dose adjustments or adverse events. For eligible maintenance patients, at-home SCIT through Curex extends this further: the same prescribed immunotherapy is self-administered at home, with the first injection and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand. Both the distributed-clinic model and the at-home model depend on meeting the safety requirements for allergen immunotherapy.